VIVOS THERAPEUTICS INC (VVOS)

US92859E2072 - Common Stock

4.25  -0.04 (-0.93%)

Fundamental Rating

3

Taking everything into account, VVOS scores 3 out of 10 in our fundamental rating. VVOS was compared to 107 industry peers in the Health Care Providers & Services industry. While VVOS seems to be doing ok healthwise, there are quite some concerns on its profitability. VVOS is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

VVOS had negative earnings in the past year.
VVOS had a negative operating cash flow in the past year.
In the past 5 years VVOS always reported negative net income.
VVOS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -81.89%, VVOS is not doing good in the industry: 91.43% of the companies in the same industry are doing better.
VVOS has a worse Return On Equity (-163.97%) than 82.86% of its industry peers.
Industry RankSector Rank
ROA -81.89%
ROE -163.97%
ROIC N/A
ROA(3y)-120.22%
ROA(5y)-110.13%
ROE(3y)-1293.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

VVOS has a better Gross Margin (60.76%) than 83.81% of its industry peers.
In the last couple of years the Gross Margin of VVOS has declined.
The Profit Margin and Operating Margin are not available for VVOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.05%
GM growth 5Y-3.47%

More info and screens

5

2. Health

2.1 Basic Checks

VVOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VVOS has been increased compared to 1 year ago.
The number of shares outstanding for VVOS has been increased compared to 5 years ago.
VVOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -9.22, we must say that VVOS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VVOS (-9.22) is worse than 91.43% of its industry peers.
VVOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.22
ROIC/WACCN/A
WACC9.22%

2.3 Liquidity

VVOS has a Current Ratio of 1.44. This is a normal value and indicates that VVOS is financially healthy and should not expect problems in meeting its short term obligations.
VVOS has a Current ratio of 1.44. This is comparable to the rest of the industry: VVOS outperforms 51.43% of its industry peers.
VVOS has a Quick Ratio of 1.44. This is a normal value and indicates that VVOS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.44, VVOS is in line with its industry, outperforming 54.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.44
Quick Ratio 1.44

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.87% over the past year.
Looking at the last year, VVOS shows a small growth in Revenue. The Revenue has grown by 0.49% in the last year.
Measured over the past years, VVOS shows a very strong growth in Revenue. The Revenue has been growing by 29.50% on average per year.
EPS 1Y (TTM)55.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.31%
Revenue 1Y (TTM)0.49%
Revenue growth 3Y1.83%
Revenue growth 5Y29.5%
Sales Q2Q%16.93%

3.2 Future

VVOS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.86% yearly.
VVOS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.05% yearly.
EPS Next Y78.98%
EPS Next 2Y37.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.72%
Revenue Next 2Y17.05%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VVOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VVOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as VVOS's earnings are expected to grow with 37.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.86%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VVOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVOS THERAPEUTICS INC

NASDAQ:VVOS (1/2/2025, 8:01:37 PM)

4.25

-0.04 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners12.54%
Inst Owner Change31.12%
Ins Owners1.53%
Ins Owner Change0%
Market Cap20.57M
Analysts82.5
Price Target6.43 (51.29%)
Short Float %3.11%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)39.84%
Min EPS beat(2)35.71%
Max EPS beat(2)43.98%
EPS beat(4)2
Avg EPS beat(4)-3.32%
Min EPS beat(4)-56.97%
Max EPS beat(4)43.98%
EPS beat(8)5
Avg EPS beat(8)10.87%
EPS beat(12)6
Avg EPS beat(12)1.49%
EPS beat(16)6
Avg EPS beat(16)-28.49%
Revenue beat(2)1
Avg Revenue beat(2)1.8%
Min Revenue beat(2)-6.81%
Max Revenue beat(2)10.4%
Revenue beat(4)1
Avg Revenue beat(4)-1.16%
Min Revenue beat(4)-6.81%
Max Revenue beat(4)10.4%
Revenue beat(8)1
Avg Revenue beat(8)-8.34%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-15.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40.6%
EPS NY rev (1m)0%
EPS NY rev (3m)32.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.03%
Revenue NY rev (1m)-10.11%
Revenue NY rev (3m)-4.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.41
P/FCF N/A
P/OCF N/A
P/B 2.68
P/tB 4.63
EV/EBITDA N/A
EPS(TTM)-5.68
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-2.7
FCFYN/A
OCF(TTM)-2.58
OCFYN/A
SpS3.01
BVpS1.58
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.89%
ROE -163.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.76%
FCFM N/A
ROA(3y)-120.22%
ROA(5y)-110.13%
ROE(3y)-1293.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.05%
GM growth 5Y-3.47%
F-Score5
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.26%
Cap/Sales 3.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.44
Quick Ratio 1.44
Altman-Z -9.22
F-Score5
WACC9.22%
ROIC/WACCN/A
Cap/Depr(3y)198.46%
Cap/Depr(5y)127.21%
Cap/Sales(3y)8.59%
Cap/Sales(5y)5.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.31%
EPS Next Y78.98%
EPS Next 2Y37.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.49%
Revenue growth 3Y1.83%
Revenue growth 5Y29.5%
Sales Q2Q%16.93%
Revenue Next Year8.72%
Revenue Next 2Y17.05%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.42%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.69%
OCF growth 3YN/A
OCF growth 5YN/A